Walden, R-Ore., motion to recommit the bill to the House Energy and Commerce Committee with instructions to report it back immediately with an amendment that would postpone the bill's effective date until the Health and Human Services Department certifies that none of the bill's provisions would adversely affect the research, development, or approval of any drug intended to treat or prevent COVID-19.